FDA Approves Caplyta for Major Depressive Disorder, Offering New Hope
TL;DR
Johnson & Johnson's FDA approval of CAPLYTA (lumateperone) as an adjunctive treatment for major depressive disorder in adults offers a new hope for remission, demonstrating efficacy and a favorable safety profile based on Phase 3 trials, potentially transforming treatment expectations for depression.
Topics:businesshealth#caplyta#fda-approval#health#lumateperone#major-depressive-disorder#mental-health
- FDA approval of CAPLYTA® (lumateperone) has the potential to reset treatment expectations, offering hope for remission in adults with major depressive disorder Johnson & Johnson
- FDA approves J&J’s antipsychotic drug to treat depression statnews.com
- FDA approval of CAPLYTA® has the potential to reset treatment expectations, offering hope for remission in adults with major depressive disorder Investing News Network
- J&J's Caplyta supersizes its reach with FDA nod as add-on treatment for major depressive disorder Fierce Pharma
- FDA Approves Lumateperone With Antidepressant Use for Major Depressive Disorder Pharmacy Times
Want the full story? Read the original reporting
Read on Johnson & Johnson